Under the Seventh Framework Programme, set to begin in 2007, the European Union will extend its research activities on HIV/AIDS. Finding new preventive technologies, vaccines and microbicides will continue to be a key aspect of the overall EC research strategy.
The Commission will further strengthen its strategic partnerships with global initiatives on HIV/AIDS, including the Alliance for Microbicide Development, a global coalition for the promotion of microbicides to protect both men and women from HIV infection. The European Commission is also a key partner in the Global HIV/AIDS Vaccine Enterprise, promoting HIV vaccine research and encouraging European researchers to collaborate with their international colleagues in the development of an effective HIV/AIDS vaccine.
In addition, the Commission will continue supporting people living with HIV/AIDS, financing research on new and better drugs, drug combinations and treatments.
The European and Developing Countries Clinical Trials Partnership (EDCTP)
The EDCTP is a major long-term initiative to accelerate the development of new clinical interventions to fight HIV/AIDS, malaria and tuberculosis in developing countries, particularly Sub-Saharan Africa. Work includes:
- Stepping up clinical trials of new and improved products, in particular drugs, vaccines and microbicides;
- Addressing the specific needs and priorities of developing countries with respect to research on HIV/AIDS;
- Networking European efforts for promoting HIV/AIDS research in Africa;
- Strengthening HIV/AIDS clinical trial capacities;
- Encouraging investment and participation by the private sector;
- Mobilising additional funds to fight HIV and AIDS.
Supported by €200 million in European Union funding within the Sixth Framework Programme, the EDCTP will continue to link European and African researchers, providing research capacity in developing countries.